STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Organon & Co. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Organon & Co. (OGN) announced that director Grace Puma will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders. She has served on the Board since 2021 and is a member of the Board’s Talent Committee.

Ms. Puma will continue to serve as a director and in her committee role until the 2026 Annual Meeting. The company stated that her decision is not due to any disagreement with the company, its management, the Board, or any committee.

Positive
  • None.
Negative
  • None.
false 0001821825 0001821825 2025-11-03 2025-11-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 3, 2025

 

Organon & Co.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40235   46-4838035
(State or other jurisdiction of   (Commission File Number)   (I.R.S. Employer Identification No.)
incorporation)    
         
30 Hudson Street, Floor 33,
Jersey City
, NJ
      07302
(Address and principal executive
offices)
      (Zip Code)

 

Registrant’s telephone number, including area code: (551) 430-6900

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.01 per share   OGN   NYSE

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 3, 2025, Grace Puma informed Organon & Co. (the “Company”) that she will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). Ms. Puma has served as a member of the Board of Directors (the “Board”) of the Company since 2021 and currently serves as a member of the Talent Committee of the Board. Ms. Puma will continue to serve as a director and in her committee role until the 2026 Annual Meeting.

 

Ms. Puma’s departure is not due to any disagreement between her and the Company, its management, the Board or any committee thereof, or any matter relating to the Company’s operations, policies or practices.

 

Exhibit No. Description
   
104The Cover Page of this Current Report on Form 8-K, formatted in Inline XBRL.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

  Organon & Co.
   
  By: /s/ Kirke Weaver
    Name: Kirke Weaver
    Title: General Counsel

 

Dated: November 7, 2025

 

 

 

ORGANON & CO

NYSE:OGN

OGN Rankings

OGN Latest News

OGN Latest SEC Filings

OGN Stock Data

1.74B
259.05M
0.25%
84.6%
5.74%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
JERSEY CITY